Home/Filings/4/0001127602-19-007251
4//SEC Filing

Ehlers Michael D 4

Accession 0001127602-19-007251

CIK 0000875045other

Filed

Feb 19, 7:00 PM ET

Accepted

Feb 20, 5:54 PM ET

Size

11.0 KB

Accession

0001127602-19-007251

Insider Transaction Report

Form 4
Period: 2019-02-15
Ehlers Michael D
EVP, Research and Development
Transactions
  • Exercise/Conversion

    Restricted Stock Unit

    2019-02-151,6853,757 total
    Exercise: $0.00Exp: 2020-02-15Common Stock (1,685 underlying)
  • Exercise/Conversion

    Common Stock

    2019-02-15+1,6858,526.171 total
  • Tax Payment

    Common Stock

    2019-02-15$332.87/sh749$249,3207,777.171 total
  • Other

    Restricted Stock Unit

    2019-02-151,0332,724 total
    Exercise: $0.00Exp: 2020-02-15Common Stock (1,033 underlying)
Footnotes (2)
  • [F1]The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]).
  • [F2]This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.

Issuer

BIOGEN INC.

CIK 0000875045

Entity typeother

Related Parties

1
  • filerCIK 0001674364

Filing Metadata

Form type
4
Filed
Feb 19, 7:00 PM ET
Accepted
Feb 20, 5:54 PM ET
Size
11.0 KB